Objective: The aim of the study was to prospectively gather data on pregnancy outcomes of prenatally diagnosed trisomy 21 (T21) in a large tertiary referral centre. Methods: Data were gathered prospectively in a large tertiary referral centre over 5 years from 2013 to 2017 inclusively. Baseline demographic and pregnancy outcome data were recorded on an anonymized computerized database. Results: There were 1,836 congenital anomalies diagnosed in the study period including 8.9% (n = 165) cases of T21. 79% (n = 131) were age 35 or older at diagnosis. 79/113 (69.9%) women chose a termination of pregnancy (TOP) following a diagnosis of T21. Amongst pregnancies that continued, there were 4 second-trimester miscarriages (4/34, 11.7%), 9 stillbirths (9/34, 26.4%), and 1 neonatal death, giving an overall pregnancy and neonatal loss rate of 14/34 (41.1%). Conclusion: The risk of foetal loss in prenatally diagnosed T21 is high at 38% with an overall pregnancy loss rate of 41.1%. This information may be of benefit when counselling couples who are faced with a diagnosis of T21 particularly in the context of limited access to TOP.

1.
Patterson
D
.
Molecular genetic analysis of Down syndrome
.
Hum Genet
.
2009 Jul
;
126
(
1
):
195
214
. .
2.
Mansfield
C
,
Hopfer
S
,
Marteau
TM
.
Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and turner and Klinefelter syndromes: a systematic literature review. European concerted action: DADA (decision-making after the diagnosis of a fetal abnormality)
.
Prenat Diagn
.
1999 Sep
;
19
(
9
):
808
12
. .
3.
EUROCAT – Surveillance of congenital anomalies in Europe; epidemiology of Down Syndrome 1990–2014.
4.
Huether
CA
,
Ivanovich
J
,
Goodwin
BS
,
Krivchenia
EL
,
Hertzberg
VS
,
Edmonds
LD
,
Maternal age specific risk rate estimates for Down syndrome among live births in whites and other races from Ohio and metropolitan Atlanta, 1970‒1989
.
J Med Genet
.
1998
;
35
:
482
90
. .
5.
Bishop
J
,
Huether
CA
,
Torfs
C
,
Lorey
F
,
Deddens
J
.
Epidemiologic study of Down syndrome in a racially diverse California population, 1989–1991
.
Am J Epidemiol
.
1997
;
145
:
134
47
.
6.
Weijerman
ME
,
de Winter
JP
.
Clinical practice. The care of children with Down syndrome
.
Eur J Pediatr
.
2010 Dec
;
169
(
12
):
1445
52
. .
7.
Nyberg
DA
,
Souter
VL
,
El-Bastawissi
A
,
Young
S
,
Luthhardt
F
,
Luthy
DA
.
Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy
.
J Ultrasound Med
.
2001 Oct
;
20
(
10
):
1053
63
. .
8.
Stoll
C
,
Dott
B
,
Alembik
Y
,
Roth
MP
.
Associated congenital anomalies among cases with Down syndrome
.
Eur J Med Genet
.
2015 Dec
;
58
(
12
):
674
80
. .
9.
Hickey
F
,
Hickey
E
,
Summar
KL
.
Medical update for children with Down syndrome for the pediatrician and family practitioner
.
Adv Pediatr
.
2012
;
59
(
1
):
137
57
. .
10.
Nicolaides
KH
,
Azar
G
,
Byrne
D
,
Mansur
C
,
Marks
K
.
Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy
.
BMJ
.
1992
;
304
:
867
9
. .
11.
Snijders
RJ
,
Noble
P
,
Sebire
N
,
Souka
A
,
Nicolaides
KH
.
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10‒14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group
.
Lancet
.
1998
;
352
:
343
6
. .
12.
Malone
FD
,
Canick
JA
,
Ball
RH
,
Nyberg
DA
,
Comstock
CH
,
Bukowski
R
,
First-trimester or second-trimester screening, or both, for Down’s syndrome
.
N Engl J Med
.
2005 Nov 10
;
353
(
19
):
2001
11
.
13.
Natoli
JL
,
Ackerman
DL
,
McDermott
S
,
Edwards
JG
.
Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995–2011)
.
Prenat Diagn
.
2012 Feb
;
32
(
2
):
142
53
.
14.
Magelssen
M
,
Solberg
B
,
Supphellen
M
,
Haugen
G
.
Attitudes to prenatal screening among Norwegian citizens: liberality, ambivalence and sensitivity
.
BMC Med Ethics
.
2018 Sep 18
;
19
(
1
):
80
.
15.
Chitty
LS
,
Wright
D
,
Hill
M
,
Verhoef
TI
,
Daley
R
,
Lewis
C
,
Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units
.
BMJ
.
2016 Jul 4
;
354
:
i3426
. .
16.
Carothers
AD
,
Hecht
CA
,
Hook
EB
.
International variation in reported livebirth prevalence rates of Down syndrome, adjusted for maternal age
.
J Med Genet
.
1999
;
36
:
386
93
.
17.
Landrum
BG
,
Johnson
DE
,
Ferrara
B
,
Boros
SJ
,
Thompson
TR
.
Hydrops fetalis and chromosomal trisomies
.
Am J Obstet Gynecol
.
1986 May
;
154
(
5
):
1114
5
.
18.
Yao
R
,
Contag
SA
,
Goetzinger
KR
,
Crimmins
SD
,
Kopelman
JN
,
Turan
S
,
The role of fetal growth restriction in the association between Down syndrome and perinatal mortality
.
J Matern Fetal Neonatal Med
.
2020 Mar
;
33
(
6
):
952
60
.
19.
Brantberg
A
,
Blaas
H
,
Salvesen
KA
,
Haugen
SE
,
Møllerløkken
G
,
Eik-Nes
SH
.
Fetal duodenal obstructions: increased risk of prenatal sudden death
.
Ultrasound Obstet Gynecol
.
2002 Nov
;
20
(
5
):
439
46
.
20.
Rankin
J
,
Tennant
PW
,
Bythell
M
,
Pearce
MS
.
Predictors of survival in children born with Down syndrome: a registry-based study pediatrics
.
Pediatrics
.
2012 Jun
;
129
(
6
):
e1373
81
.
21.
Choi
H
,
Van Riper
M
,
Thoyre
S
.
Decision making following a prenatal diagnosis of Down syndrome: an integrative review
.
J Midwifery Womens Health
.
2012 Mar–Apr
;
57
(
2
):
156
64
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.